GlassScriptPhysician profile
Matthew Scott Forcina
NPI 1629286125
$11,021.82
in general payments reported to CMS, 2019-2025
43 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,246 · 2020: $1,036 · 2021: $1,924 · 2022: $1,463 · 2023: $1,911 · 2024: $1,151 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,353.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,123.80 | 2019-2025 | |
| Amgen INC. | $1,046.92 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $993.00 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $989.77 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $863.36 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $778.55 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $720.90 | 2019-2024 | Brilinta, Farxiga |
| Amarin Pharma, INC. | $587.57 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $514.31 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.19 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $428.00 | 2020-2025 | Nexletol |
| Pfizer INC. | $335.05 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $203.92 | 2020-2025 | Onpattro |
| Astellas Pharma US INC | $194.20 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $164.71 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $161.12 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $149.86 | 2023 | Arcalyst |
| Novo Nordisk INC | $143.74 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $112.49 | 2019-2025 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $95.29 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $90.00 | 2021-2025 | |
| Abbott Laboratories | $76.42 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Baxter Healthcare | $71.24 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Preventice Services, LLC | $64.26 | 2019-2021 | |
| Scpharmaceuticals INC. | $62.83 | 2025 | |
| Philips North America LLC | $60.96 | 2020-2024 | (5044) Mcot |
| Bardy Diagnostics, INC. | $59.32 | 2019-2021 | |
| Boston Scientific Corporation | $53.71 | 2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Heartflow, INC. | $47.71 | 2022-2023 | Ffrct |
| Kowa Pharmaceuticals America, INC. | $47.49 | 2021-2022 | |
| Glaxosmithkline, LLC. | $40.30 | 2025 | Arexvy, Shingrix |
| Braemar Manufacturing, LLC | $38.77 | 2019 | |
| Vital Connect, INC | $36.01 | 2025 | Vitalpatch Rtm |
| Arbor Pharmaceuticals, INC. | $35.94 | 2020-2021 | |
| Medtronic Vascular, INC. | $31.58 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $26.67 | 2024 | Arcalyst |
| Gilead Sciences, INC. | $25.14 | 2019 | |
| Cashflow Solutions, LLC | $21.49 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Irhythm Technologies, INC. | $19.95 | 2023 | Zio Xt Patch |
| Medtronic, INC. | $18.41 | 2022 | |
| Becton, Dickinson and Company | $17.16 | 2019 | |
| Abiomed | $16.38 | 2024 | |
| Biotronik INC. | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Forcina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.